Asia Cervical Cancer Screening Market will reach US$ 4.5 Billion by 2028

Renub Research has recently published a report named “Asia Cervical Cancer Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2028,” providing a detailed industry analysis that consists of market share insights. Furthermore, the report encompasses a study of competitors and regions and the recent growth in the Asia Cervical Cancer Screening Market.


Expert Insights: Ask Analyst or Download Full Report with TOC & Figures:


Asia Cervical Cancer Screening Market is anticipated to grow significantly between 2022 and 2028, with a CAGR of 3.79%.Cervical cancer is a significant health issue worldwide and ranks seventh in terms of overall cancer incidences.The risk of developing cervical cancer affects 1786,49 million women in Asia who are 15 years of age or older. Every year, 351,720 women are diagnosed with cervical cancer, and 199,902 of them die from the disease, according to estimates from the HPV Information Centre. Cervical cancer is the fourth most prevalent cancer in women in Asia.


Precancerous or cancerous changes in the cervix are found through cervical cancer screening. It has been recommended that women over 30 get routine Pap tests, though this may change depending on risk factors and clinical guidelines. Precancerous changes in the cervix should be identified during screening in order to be treated before they progress to full-blown cancer. Women’s deaths from cervical cancer might be avoided thanks to this early detection.


There is a growing need for diagnostic procedures like colposcopy and pelvic exams to give doctors a clearer picture of the abnormal tissues as a result of the rising prevalence of cervical cancer in the area. Women who exhibit symptoms and indicators of cervical cancer can also get support from diagnostic centers to take part in a variety of diagnostic exams, such as pap and HPV testing. These facilities will increasingly employ some of the most cutting-edge techniques for cervical cancer diagnosis, which will hasten the market’s expansion.


Favorable government initiatives for cervical cancer prevention, an increase in the prevalence of the disease, increased awareness of early detection, and strong R&D from major players in cervical cancer diagnosis and drugs are the main factors propelling market growth. Organizations are starting to train gynecologists and nurses in the early detection of cervical cancer cases. The market expansion is aided by these programs’ support for cervical cancer early detection and treatment. As more potent test-medication combinations are developed, the market is also anticipated to grow.


Request a free sample copy of the report:


In the upcoming years, it is anticipated that demand for cervical cancer screening in Japan will increase.


Cervical cancer awareness has increased thanks to the government’s active promotion of the benefits of screening, which has sped up the market for cervical cancer screening in Japan. The creation of enhanced screening techniques, such as HPV testing, has enabled early detection and decreased the number of fatalities from cervical cancer. Furthermore, the government’s initiatives to subsidize screening services have made screenings more accessible to people of all income levels. The primary cause of cervical cancer, HPV infections, have decreased as a result of the recommendation of HPV vaccination for girls starting in 2013.


Countries – Asia cervical cancer screening market is divided in seven countries.


1.       Japan

2.       Korea

3.       Singapore

4.       Malaysia

5.       India

6.       China

7.       Indonesia

The Asia cervical cancer market share leader in the country segment for Pap smears is Japan.


Japan has established itself as a leader in the Pap smear industry thanks to its early adoption of Pap smears as a routine method of cervical cancer screening and the government’s unwavering support in the form of funding for research and development and subsidies for screening services. Leading businesses with a track record of innovation are present, which reinforces Japan’s hegemony. The demand for Pap smear products is also expected to rise significantly due to the high percentage of women in society and the growing recognition of the value of routine screening. Together, these elements guarantee Japan’s continued leadership in advancing cervical cancer screening, which benefits women’s health both within and outside of Japan.


Pap smear – Asia cervical cancer screening market consists of eight countries.


1.    Japan

2.    Korea

3.    Singapore

4.    Malaysia

5.    India

6.    China

7.    Thailand

8.    Indonesia


The HPV DNA market in Japan is expanding at the fastest rate in the Asia cervical cancer screening sector.


HPV DNA testing has become more popular as a preventative measure as a result of rising awareness of HPV and its connection to cervical cancer. The development of this market has been facilitated by Japan’s advances in medical technology, established healthcare infrastructure, and public-private sector cooperation. Demand has also increased as a result of more people requesting HPV DNA testing during routine health examinations due to the growing emphasis on preventive healthcare.


HPV DNA – Asia cervical cancer screening market covers seven countries.


1.    Japan

2.    Korea

3.    Singapore

4.    Malaysia

5.    India

6.    China

7.    Indonesia


India’s potential dominance in the Visual Inspection with Acetic Acid (VIA) segment is evident due to its substantial market with a large population of women.


Many women in the nation can use VIA as a screening method because it is inexpensive. VIA’s prominence is increased by the proactive support of the Indian government, including funding for training and awareness initiatives. Its market position is further strengthened by the availability of skilled healthcare professionals who can perform VIA screening. India’s high cervical cancer prevalence further emphasizes the urgent need for VIA screening. India has a good chance of snatching up a sizeable chunk of the VIA market thanks to rising awareness of cervical cancer, easier access to healthcare, and various government initiatives.


VIA (visual inspection with acetic acid) – Four Countries have been covered in the Asia cervical cancer screening market.


1.    India

2.    China

3.    Thailand

4.    Indonesia


Competitive Landscape.


Several well-known companies are active in the Asia cervical cancer screening market, including AstraZeneca, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health.


Companies have been covered from 3 viewpoints


•    Overview

•    Recent Development

•    Sales


Company Covered


1.    AstraZeneca

2.    Hologic Corporation

3.    Becton

4.    Siemens AG

5.    Roche Diagnostics

6.    Quest Diagnostics

7.    Cardinal Health


Related Reports


Asia Breast Cancer Screening Market, Size, Forecast 2023-2028

Breast Cancer Screening Market, Size, Global Forecast 2023-2028

Europe Cervical Cancer Screening Market, Size, Forecast 2023-2028

Europe Breast Cancer Screening Market, Size, Forecast 2023-2028

Cervical Cancer Screening Market, Size, Global Forecast 2023-2028


About the Company: 

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.


Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Address: 225 Kristie Ln, Roswell, GA 30076




Leave a Reply

Your email address will not be published. Required fields are marked *